Search company, investor...

Total Raised

$129.3M

Investors Count

26

Deal Terms

3

Funding, Valuation & Revenue

11 Fundings

Paratek Pharmaceuticals has raised $129.3M over 11 rounds.

Paratek Pharmaceuticals's latest funding round was a Take Private for on September 20, 2023.

Paratek Pharmaceuticals's valuation in May 2006 was $145.08M.

Paratek Pharmaceuticals's latest post-money valuation is from September 2023.

Sign up for a free demo to see Paratek Pharmaceuticals's valuations in September 2023 and more.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

9/20/2023

Take Private

$99M

$0.00B

((9.99x))

FY 1234

10

1/6/2021

Loan

$60M

$99M

$75M - $80M

FY 2020

4

7/15/2014

PIPE - II

$93M

Undisclosed Investors

$99M

0

FY undefined

1

4/7/2008

PIPE

$99M

$99M

0

FY undefined

0

5/10/2006

IPO

$99M

$145.08M

0

FY undefined

0

Date

9/20/2023

1/6/2021

7/15/2014

4/7/2008

5/10/2006

Round

Take Private

Loan

PIPE - II

PIPE

IPO

Amount

$60M

$93M

$99M

$99M

Investors

Undisclosed Investors

Valuation

$99M

$99M

$99M

$99M

$145.08M

Revenue

$0.00B

((9.99x))

FY 1234

$75M - $80M

FY 2020

0

FY undefined

0

FY undefined

0

FY undefined

Sources

10

4

1

0

0

You're one click away from the most comprehensive, unmatched analyst expertise in tech, in-depth private company data and a platform that brings it all together.
Click Now. Join a live demo
Join a demo
CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

Paratek Pharmaceuticals Deal Terms

3 Deal Terms

Paratek Pharmaceuticals's deal structure is available for 3 funding rounds, including their Take Private from September 20, 2023.

Round

Take Private

IPO

Series A

Funding Date

$99M

$99M

$99M

Pre-Money Valuation

$99M

Post-Money Valuation

$99M

$99M

Amount Raised

$99M

$99M

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

$99M

$99M

$99M

Board Voting

$99M

$99M

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Take Private

$99M

$99M

$99M

$99M

IPO

$99M

$99M

$99M

$99M

$99M

$99M

Series A

$99M

$99M

$99M

$99M

Paratek Pharmaceuticals Investors

26 Investors

Paratek Pharmaceuticals has 26 investors. Novo Holdings invested in Paratek Pharmaceuticals's Take Private funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

9/20/2023

9/20/2023

1
Take Private

Holding Company

Denmark

9/20/2023

9/20/2023

1
Take Private

Private Equity

Massachusetts

1/6/2021

1/6/2021

1
Loan

Private Equity

Singapore

00/00/0000

00/00/0000

Biofund

Subscribe to see more

Venture Capital

Finland

00/00/0000

00/00/0000

Nomura Holdings

Subscribe to see more

Diversified Financial Services

Japan

First funding

9/20/2023

9/20/2023

1/6/2021

00/00/0000

00/00/0000

Last Funding

9/20/2023

9/20/2023

1/6/2021

00/00/0000

00/00/0000

Investor

Biofund

Nomura Holdings

Rounds

1
Take Private
1
Take Private
1
Loan

Subscribe to see more

Subscribe to see more

Board Seats

Type

Holding Company

Private Equity

Private Equity

Venture Capital

Diversified Financial Services

Location

Denmark

Massachusetts

Singapore

Finland

Japan

Paratek Pharmaceuticals Acquisitions

1 Acquisition

Paratek Pharmaceuticals acquired 1 company. Their latest acquisition was Transcept Pharmaceuticals on October 31, 2014.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

10/31/2014

Series D

$99M

$70.5M

Acq - P2P

1

Date

10/31/2014

Investment Stage

Series D

Companies

Valuation

$99M

Total Funding

$70.5M

Note

Acq - P2P

Sources

1

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

Compare Paratek Pharmaceuticals to Competitors

B
Bolder BioTechnology

Bolder BioTechnology, Inc. uses advanced protein engineering technologies to create human protein pharmaceuticals with enhanced therapeutic properties. Most protein pharmaceuticals are rapidly eliminated by the body, which limits their effectiveness and requires that they be administered by frequent, often daily, injection. The company's products are designed to last longer in the body, which aims to allow them to be administered less frequently, e.g., once per week to once per month, and maximizes their therapeutic benefits to patients. Company scientists combine protein structure/function information with targeted protein modification technologies to rationally design long-acting protein pharmaceuticals that, in many cases, are 10-100-fold more potent than competing products prepared using non-targeted protein modification technologies. Bolder BioTechnology has a robust pipeline of products in preclinical development, including products for the treatment of hematological and endocrine disorders, cancer and infectious disease. The company intend to commercialize these products independently and through strategic alliances with corporate partners.

S
Spaltudaq

Spaltudaq is a company that specializes in the construction industry, with a focus on roofing services. The company offers a range of services including roof installation, roof replacement, and roof repair, catering to both residential and commercial needs. These services are designed to ensure the durability and longevity of roofing systems, providing protection and security for buildings. It was founded in 2004 and is based in Seattle, Washington.

Longevica Logo
Longevica

Longevica is a biotechnology that is researching mechanisms of healthy aging and life extension. The company is also developing an open research tool for scientists and research institutions to access a data set that tracks the effects of pharmacological compounds for testing drugs.

A
Arisyn Therapeutics

Arisyn Therapeutics Inc. is a biotechnology company focused on the development of first in class inhibitors of infectious disease and cancer. Arisyn possesses a portfolio of small molecule compounds that will be developed to treat Human Immunodeficiency Virus-Type 1 (HIV-1), Human Immunodeficiency Virus-Type 2 (HIV-2), Human T-Lymphotropic Virus-Type 1 (HTLV-1), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Herpes Simplex Virus-Type 2 (HSV-2). Arisyn will perform all necessary studies required to develop these therapeutic agents through Phase 1 and Phase 2 human clinical trials.

Q
Qwell Pharmaceuticals

Qwell Pharmaceuticals is a biotechnology company focused on small molecule development primarily for oncology indications.

A
Abunda

Abunda is a financial advisory firm specializing in wealth management and financial planning. The company offers a range of services including investment management, financial advisory, tax services, and personal finance education. Abunda primarily caters to individuals seeking to preserve and grow their wealth through conservative strategies. It is based in San Francisco, California.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.